Anti-CD79b Antibody (Polatuzumab vedotin-piiq)
Catalog No.
F1126
Anti-CD79b Antibody (Polatuzumab vedotin-piiq)
Featured Products
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody against CD79b (a component of the B-cell receptor) and the anti-mitotic antibody cytotoxic agent monomethyl auristatin (MMAE). It is used to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
150.53 kDa
Dry ice
1313206-42-6
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Polivy, RG7596, DCDS4501A
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P40259
Human
MMAE
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
The drug-to-antibody ratio (DAR) of the Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) is 3.8.
CD79b
Please avoid freeze-thaw cycles.